Comparative safety and sedation effectiveness of intranasal dexmedetomidine versus midazolam for preoperative anxiety reduction in pediatric surgical patients: an updated systematic review and meta-analysis
Hany A Zaki, Hussam Elmelliti, Ahmed Shaban, Amira Shaban, Ali Elkandow, Mohamed Gafar Abdelrahim, Mohamed Ezzat Jawad, Mohamed F Abosamak, Eman E Shaban · 2026
Read Comparative safety and sedation effectiveness of intranasal dexmedetomidine versus midazolam for preoperative anxiety reduction in pediatric surgical patients: an updated systematic review and meta-analysis by Hany A Zaki, Hussam Elmelliti, Ahmed Shaban, Amira Shaban, Ali Elkandow, Mohamed Gafar Abdelrahim, Mohamed Ezzat Jawad, Mohamed F Abosamak, Eman E Shaban (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13326389.txt.
Description
Hany Zaki and co-authors pool trials of two nose-spray sedatives for anxious children before surgery in a review from 2026. Fear before an operation is a top worry for child anesthesiologists. Midazolam is the long-standing choice, but it can cause agitation, memory gaps, and slowed breathing.
Dexmedetomidine, given through the nose, is the challenger drug. The review searched four major databases for head-to-head trials. Both nose and mouth routes of midazolam served as controls. Pooled results weigh calmness scores against side effects. Parents and surgeons want a child who arrives calm and wakes clear. An updated pooled verdict can settle which spray clinics should stock first.
Catalog record
| CREATOR | Hany A Zaki, Hussam Elmelliti, Ahmed Shaban, Amira Shaban, Ali Elkandow, Mohamed Gafar Abdelrahim, Mohamed Ezzat Jawad, Mohamed F Abosamak, Eman E Shaban |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |